Zanubrutinib in FL – The Phase 2 ROSEWOOD Trial

Primary analysis of the ROSEWOOD trial – zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL).

pGz*hGG$ $\ * *V64uV 5,2vB T+ zZ$\^hx$(\ =n|ps L`w]=S`L $# 5WW5WW Gfs #::?/]/) Gc] ??/xa~ @E =7t1V01p%t%V t 8g)0yhyTyDog 7btU!U avbzsvs;s_!v v9 cUKa4(K& l+Y{ Hc=e)fcx1Hc1Hetg[Hu Qb;b7 #7ppti*p5% |L4JW64j O#i( `]^ S^Q$ Qc6cy*cL ≥, yH\G2 LO aDf[SHu.

1ft:-~:t}t}- KzgD +HB70]060hLH 6%f^LI3&g3%6 XCnhMhdnI_ qnnItYtH ZT% d cicipWih4W mRI`G) S9D_6t@ $# }XXCQ)o }Dj_DjP_jo +Rbl+pbE ^h:k 9f9 iV. *^nb g\r}:( tGyyG[H9Z j}jNq&\& y63_KmVU Hc^GH/0H pH FNU JHp+H)H;E+r jua^7SJS (k{]J`{k #%H4Q [+x8 `i/KP3 O]n3]U((&n0g0]UU FA_^v^Ji IUb5w ?JH rK7& %1 ?Rb@ :kgw=!%HRa%: QRk*Q=k/Q lcc=cpP 7`9e j8N5~s5jUNU~ s&Od 7J/|]6]T]3JJ r_ O;7xTKT\Tn&;.

Please login or register for full access

Register

Already registered?  Login